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Objective: Randomized clinical trials have shown a protective effect of the an-
tihypertensive therapy on cardiovascular outcomes and all-cause death extending 
to elderly patients. Evidence is limited in frail old patients with a short life ex-
pectancy who have normally been excluded from trials. Aim of our study was to 
assess whether adherence to antihypertensive drugs is accompanied by a reduced 
risk of death and cardiovascular events in frail vs non-frail elderly individuals 
based on different life expectancies.
Design and method: We identified from the Lombardy database the 1,183,201 
residents aged >=65 years who had >=3 prescriptions of antihypertensive drugs 
between 2007–2009. A nested case-control design was applied. Cases were the 
cohort members who died or had hospital admission for cardiovascular events 
until 2012. Logistic regression was used to model the association between ad-
herence with antihypertensive treatment and outcome risk. The analysis was 
separately performed in four clinical categories, i.e. patients with a good, me-
dium, poor, and very poor clinical status, as assessed by a score prognostic 
index (MCS) based on 34 weighted cardiovascular and non-cardiovascular 
morbidities that has been shown to be a more sensitive predictor of death and 
hospitalization in the Italian population than other largely used scores. From 
the good to the very poor clinical status, the 6-year death probability increased 
from 12 to 58%.
Results: Compared with patients with very low adherence to antihypertensive 
treatment, those with high adherence exhibited a lower risk of all-cause mortality 
in each clinical status. The reduction in risk was 52%, 49%, 43% and 34% in the 
good, medium, poor and very poor clinical categories, respectively. Adherence 
to antihypertensive drug treatment was also associated with hospitalization for 
cardiovascular diseases among patients with a good or medium clinical status. In 
contrast, there was no evidence that drug adherence affected the risk of cardiovas-
cular disease in patients with a poor or very poor clinical status.
Conclusions: Adherence to antihypertensive treatment reduced the risk of death 
in frail elderly patients. This was not the case for the risk of cardiovascular hospi-
talization. More studies are needed to understand the reason for this discrepancy.
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Objective: Environmental or genetic factors, together with the interaction be-
tween them, may explain the increasing population of centenarians. This research 
aimed to understand these interactions that underlie centenarian’s phenotypes, 
namely gene-gene and gene-environment, particularly in relation to cardiovas-
cular risk (CVR).
Design and method: A sample of 521 subjects both genders, 253 centenarians 
(100.26 ± 1.98 years), and 268 controls (67.5 ± 13.25 years) subdivided into low 
(LCR, n = 107) and high (HCR, n = 161) CVR were included. Hypertension, dia-
betes, obesity (BMI, Kg.m-2) and impaired kidney function, were defined accord-
ing to standard criteria. CVR was calculated using Q risk 2–2016. DNA extraction 
was performed from the buccal epithelium sample using CitogeneâBuccal Kit, 
genotyping through iPlex-MassARRAYâ, read by MALDI-TOF mass spectrom-
etry and analyzed by EARTDECODEâ. Statistics were done throughout MDR and 
SPSS softwares. Significance defined as P-value <0.05.
Results: The variables that most were with the risk of not achieving exceptional 
longevity, OR (95% CI), were: BMI 1.558 (1.445–1.680), hypertension 2.358 
(1.565–3.553), smoking-habits 4.528 (2.579–7.949), diabetes 5.553 (2.889–
10.675), hypercholesterolemia 1.016 (1.010–1.022) and regular consumption of 
red meat 22.363 (13.987–35.755). There were differences in frequencies geno-
typic between centenarians and controls in ACE I/D, rs4646994 (p = 0.001) and 
NOS3 GT, rs1799983 (p < 0.0001) polymorphisms, being ACE DD and NOS3 
GG genotypes more frequent in centenarians than in controls. No significant 
differences were observed concerning: AGT-rs699; AGT-rs4762; AGR1-rs5182; 
GRK4-rs2960306; GRK4-rs1024323; SLC12A3-rs13306673. There is a close 
genotype interaction between ACE and NOS3 each other and with hypertension, 
hypercholesterolemia, smoking and red meat intake. There is a predominance of 
Q risk marker (mainly environmental-related) associated with longevity in inter-
action to ACE I/D and NOS3.
Conclusions: In longevity pathway, even there is a gene-gene interaction particu-
larly regarding ACE and NOS3, there is also increasing interaction between genes 
related to CVR, with the predominantly environmental factors that form the basis 
of Q risk determination. underlie factors may modify gene expression modulated 
by the genotype and influence aging process.
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Objective: Pulse pressure amplification (PPA) is considered a non-dimensional 
marker of early vascular ageing, and is inversely and independently associated to 
future CV events. It is acknowledged that PPA is influenced by heart rate (HR) 
and its related changes. We aimed at evaluating the effect of ageing on the HR 
dependence of PPA.
Design and method: In a cohort of 675 never-treated hypertensives (age range 
18 to 89 years, mean age 47 ± 11 years, 56% men), at low-to-intermediate CV risk 
and without signs of hypertension-mediated organ damage, PPA and simultaneous 
HR were calculated from radial tonometry and estimated aortic pressure wave-
form through a radial-to-aortic generalized transfer function (SphygmoCor). The 
significance of the interaction term ``age (young=below mean, old=above mean) 
X HR’’ as an independent predictor of PPA, was tested in a linear multivariate re-
gression model after accounting for the non-linearity of the relationship between 
age and PPA, and the effect of other confounders (sex, height, carotid-femoral 
pulse wave velocity).
Results: Mean PPA was 1.28 ± 0.15, mean HR 66 ± 11 bpm. HR was positively 
and strongly correlated to PPA (p < 0.01), explaining one fifth of its variance. The 
curvilinear relationship between age and PPA was best described by an inverse 
logarithmic equation (p for R change vs linear = 0.04). The interaction term ``age 
X HR’’ was positively related to PPA after adjusting for multiple confounders (p 
< 0.01). The slope of the relationship between HR and PPA was steeper in old vs 
young individuals (7.4% vs 5.3% each 10 bpm increase, p for slope difference = 
0.02).
Conclusions: In our cohort, age is a significant effect-modifier of the relationship 
between HR and PPA. Ageing could be associated to more pronounced changes in 
PPA in response to HR changes. This may suggest a higher central hemodynamic 
load during low output states (e.g. during night or under the effect of HR-lowering 
drugs) in old vs young subjects.
